RLYB
Rallybio Corp
NASDAQ: RLYB · HEALTHCARE · BIOTECHNOLOGY
$16.88
+0.75% today
Updated 2026-09-11
Market cap
$89.88M
P/E ratio
2.12
P/S ratio
139.13x
EPS (TTM)
$7.99
Dividend yield
—
52W range
$4 – $18
Volume
0.0M
Rallybio Corp (RLYB) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$16.88
12-Month target
—
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.0B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 2.12x (capped 25x) · Margin: 7,051.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.